Literature DB >> 8260123

Possible interaction between phenobarbital, carbamazepine and itraconazole.

M Bonay1, A P Jonville-Bera, P Diot, E Lemarie, M Lavandier, E Autret.   

Abstract

We report a case of a possible interaction between itraconazole, phenobarbital and carbamazepine. The first plasma itraconazole concentration, measured when the patient had been taking phenobarbital for 2 months, was very low. The second measurement, 2 months after withdrawing phenobarbital, was higher but below the therapeutic range. However, carbamazepine, a well known enzyme inducer, had been initiated 15 days before. 20 days after carbamazepine was withdrawn, the itraconazole concentration 4 hours after administration was near the lower end of the therapeutic range. The mechanism of this possible interaction is probably the same for phenobarbital and carbamazepine, involving hepatic microsomal enzyme system induction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8260123     DOI: 10.2165/00002018-199309040-00008

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  11 in total

Review 1.  Laboratory monitoring of antifungal chemotherapy. British Society for Antimicrobial Chemotherapy Working Party.

Authors: 
Journal:  Lancet       Date:  1991-06-29       Impact factor: 79.321

2.  Itraconazole and anti-tuberculosis drugs.

Authors:  M Blomley; E L Teare; A de Belder; Y Thway; M Weston
Journal:  Lancet       Date:  1990-11-17       Impact factor: 79.321

3.  Potentiation of action of warfarin by itraconazole.

Authors:  J Yeh; S C Soo; C Summerton; C Richardson
Journal:  BMJ       Date:  1990-09-29

4.  Cyclosporine and itraconazole interaction in heart and lung transplant recipients.

Authors:  M R Kramer; S E Marshall; D W Denning; A M Keogh; R M Tucker; J N Galgiani; N J Lewiston; D A Stevens; J Theodore
Journal:  Ann Intern Med       Date:  1990-08-15       Impact factor: 25.391

5.  Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man.

Authors:  J M Hansen; K Siersboek-Nielsen; L Skovsted
Journal:  Clin Pharmacol Ther       Date:  1971 May-Jun       Impact factor: 6.875

6.  Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results.

Authors:  B Dupont; E Drouhet
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

7.  An evaluation of itraconazole in the management of onychomycosis.

Authors:  R J Hay; Y M Clayton; M K Moore; G Midgely
Journal:  Br J Dermatol       Date:  1988-09       Impact factor: 9.302

Review 8.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

Review 9.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

10.  Effects of carbamazepine on valproic acid kinetics in normal subjects.

Authors:  T A Bowdle; R H Levy; R E Cutler
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

View more
  10 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 2.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 3.  Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients.

Authors:  R Heylen; R Miller
Journal:  Genitourin Med       Date:  1996-08

Review 4.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 6.  Systemic antifungal agents. Drug interactions of clinical significance.

Authors:  E Albengres; H Le Louët; J P Tillement
Journal:  Drug Saf       Date:  1998-02       Impact factor: 5.606

Review 7.  Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.

Authors:  M Haria; H M Bryson; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 8.  Optimisation of itraconazole therapy using target drug concentrations.

Authors:  J M Poirier; G Cheymol
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

Review 9.  The enzymatic basis of drug-drug interactions with systemic triazole antifungals.

Authors:  Yasmine Nivoix; Dominique Levêque; Raoul Herbrecht; Jean-Claude Koffel; Laurence Beretz; Genevieve Ubeaud-Sequier
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 10.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.